专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06797267B2 Use of cytokines and mitogens to inhibit pathological immune responses 有权
公开(公告)号：US06797267B2
公开(公告)日：2004-09-28
申请号：US10028944
申请日：2001-12-21
申请人： David A. Horwitz
发明人： David A. Horwitz
IPC分类号： A61K4500
CPC分类号： A61K35/17 , C12N5/0636 , C12N2501/15 , C12N2501/23 , C12N2501/599
摘要： The invention is generally related to methods of treating autoimmune diseases, including both antibody-mediated and cell-mediated disorders.

2. 发明授权

US06713053B1 Use of IL-7 for treating auto-immune diseases and insulin-dependent diabetes mellitus in particular 有权
标题翻译：特别是使用IL-7治疗自身免疫性疾病和胰岛素依赖型糖尿病
公开(公告)号：US06713053B1
公开(公告)日：2004-03-30
申请号：US09125168
申请日：1998-08-18
申请人： Jean Francois Bach , Jean Marc Gombert , Andre Herbelin , Michel Morre
发明人： Jean Francois Bach , Jean Marc Gombert , Andre Herbelin , Michel Morre
IPC分类号： A61K4500
CPC分类号： A61K35/17 , A61K38/2046
摘要： The use of interleukin 7 or T cells pre-incubated in the presence of IL-7 for preparing a drug or pharmaceutical composition for treating an auto-immune disease, particularly an auto-immune disease induced by a defect in CD4+ T cell immunoregulation, is disclosed.
摘要翻译：使用在IL-7存在下预培养以制备用于治疗自身免疫疾病的药物或药物组合物的白细胞介素7或T细胞，特别是由CD4 + T细胞免疫调节中的缺陷诱导的自身免疫疾病，是披露

3. 发明授权

US06703421B1 Methods of using phenylmethylbenzoquinone and hydroquinone compounds for treatment of myocarditis, dilated cardiomyopathy and heart failure 有权
标题翻译：使用苯甲基苯醌和氢醌化合物治疗心肌炎，扩张型心肌病和心力衰竭的方法
公开(公告)号：US06703421B1
公开(公告)日：2004-03-09
申请号：US09856072
申请日：2001-05-17
申请人： Yoichi Nunokawa , Akira Matsumori
发明人： Yoichi Nunokawa , Akira Matsumori
IPC分类号： A61K4500
CPC分类号： A61K31/00 , A61K31/122 , A61K31/165 , A61K31/192 , A61K31/216 , A61K31/519 , A61K31/52
摘要： A method for prevention or treating myocarditis, dilated cardiomyopathy and heart failure comprising administering to a patient in need of such treatment a NF-&kgr;B inhibitor in a therapeutically effective amount, wherein said NF-&kgr;B inhibitor is a benzoquinone derivative represented by the following formula (I): wherein R1, R2 and R3 are each independently a hydrogen atom, an alkyl group having 1 to 5 carbons or an alkoxy group having 1 to 5 carbons; R4 is a hydrogen atom, a hydroxymethyl group, an alkyl group, or a carboxyl group which is optionally esterified or amidated; Z is and n is an integer from 0 to 6, or its hydroquinone form, or a pharmaceutically acceptable salt thereof, is provided.
摘要翻译：一种预防或治疗心肌炎，扩张型心肌病和心力衰竭的方法，包括向需要这种治疗的患者施用治疗有效量的NF-κB抑制剂，其中所述NF-κB抑制剂是由下式表示的苯醌衍生物 I）：其中R1，R2和R3各自独立地为氢原子，具有1至5个碳原子的烷基或具有1至5个碳原子的烷氧基; R 4为氢原子，羟甲基，烷基，或任选被酯化或酰胺化的羧基; Z是且n是0至6的整数，或其氢醌形式或其药学上可接受的盐。

4. 发明授权

US06685930B1 Methods and substances for recruiting therapeutic agents to solid tumors 失效
标题翻译：将治疗剂引入实体瘤的方法和物质
公开(公告)号：US06685930B1
公开(公告)日：2004-02-03
申请号：US08855744
申请日：1997-05-08
申请人： Tse Wen Chang
发明人： Tse Wen Chang
IPC分类号： A61K4500
CPC分类号： C07K16/468 , A61K9/1271 , A61K38/00 , A61K47/6879 , A61K47/6893 , A61K47/6913 , B82Y5/00 , C07K2319/00
摘要： Disclosed is a method of using bifunctional binding molecules, such as two linked VH-VL single chain binding molecules, to recruit a therapeutic agent to a solid tissue site. The therapeutic agent is administered separately from the binding molecules and following the administration of a remover substance which aids in clearing free binding molecules in the circulation. In the preferred mode of the invention, the binding molecules have one specificity for antigens at the target site and one for the therapeutic agent. The binding molecules are administered and allowed time to approach a maximum concentration in the extravascular space. A remover substance, preferably a liposome conjugated with antibodies which are reactive with an antigenic epitope on the binding molecules, is then administered to remove excess binding molecules from the circulation and the extravascular space. A therapeutic agent, preferably a cytotoxic drug such as ricin A chain modified so as to enable it to enter the target cells once delivered to the target site, is then administered.
摘要翻译：公开了使用双功能结合分子（例如两个连接的VH-VL单链结合分子）将治疗剂募集到固体组织部位的方法。治疗剂与结合分子分开施用，并且在施用有助于清除循环中的游离结合分子的去除剂物质后。在本发明的优选方式中，结合分子对靶位点的抗原具有一个特异性，而对治疗剂具有一个特异性。施用结合分子并允许时间接近血管外空间的最大浓度。然后施用去除剂物质，优选与抗体结合的脂质体，其与结合分子上的抗原表位反应，以从循环和血管外空间中除去过量的结合分子。然后施用治疗剂，优选细胞毒性药物如蓖麻毒蛋白A链修饰，以使其能够一旦递送至靶位点进入靶细胞。

5. 发明授权

US06638518B1 Method for inhibiting inflammatory responses 有权
标题翻译：抑制炎症反应的方法
公开(公告)号：US06638518B1
公开(公告)日：2003-10-28
申请号：US09510031
申请日：2000-02-22
申请人： Timothy L. Ratliff , Joel N. Kline
发明人： Timothy L. Ratliff , Joel N. Kline
IPC分类号： A61K4500
CPC分类号： A61K38/164 , C07K14/35
摘要： The present invention provides methods for treating at least one symptom of an inflammatory response in a mammal by administering a polypeptide to the mammal. The polypeptide can be a microbial polypeptide, or a Mycobacterial polypeptide. The present invention further provides an inflammation reaction inhibiting composition that includes a microbial polypeptide and a pharmaceutically acceptable carrier.
摘要翻译：本发明提供了通过向哺乳动物施用多肽来治疗哺乳动物炎症反应的至少一种症状的方法。多肽可以是微生物多肽或分枝杆菌多肽。本发明还提供了包含微生物多肽和药学上可接受的载体的炎症反应抑制组合物。

6. 发明授权

US06632425B1 Chemokine compositions 失效
标题翻译：趋化因子组合物
公开(公告)号：US06632425B1
公开(公告)日：2003-10-14
申请号：US09215160
申请日：1998-12-18
申请人： Yuling Li , Mark Oelkuct , Reiner L. Gentz
发明人： Yuling Li , Mark Oelkuct , Reiner L. Gentz
IPC分类号： A61K4500
CPC分类号： C07K14/50 , C07K1/113 , C07K1/36 , C07K14/521
摘要： The present invention relates to processes for the purification of proteins. More specifically, methods for solubilizing and purifying proteins expressed in an insoluble form using low concentrations of chaotropic agents, such as guanidine salts, are provided. Also provided are methods for refolding proteins solubilized according to the present invention.
摘要翻译：本发明涉及蛋白质纯化方法。更具体地，提供了使用低浓度的离液剂如胍盐增溶和纯化以不溶形式表达的蛋白质的方法。还提供了用于重折叠根据本发明溶解的蛋白质的方法

7. 发明授权

US06605272B2 Methods of using zalpha11 ligand 有权
标题翻译：使用zalpha11配体的方法
公开(公告)号：US06605272B2
公开(公告)日：2003-08-12
申请号：US09923246
申请日：2001-08-03
申请人： Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
发明人： Julia E. Novak , Scott R. Presnell , Cindy A. Sprecher , Donald C. Foster , Richard D. Holly , Jane A. Gross , Janet V. Johnston , Andrew J. Nelson , Stacey R. Dillon , Angela K. Hammond
IPC分类号： A61K4500
CPC分类号： C07K14/001 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A61K38/00 , A61K38/18 , C07K14/52 , C07K14/535 , C07K14/54 , C07K14/5406 , C07K14/715 , C07K16/24 , C07K16/2866 , C07K2317/73 , C07K2319/00 , C07K2319/21 , C07K2319/24 , C07K2319/30 , C07K2319/55 , C12N15/62 , C12N15/8509 , C12N2799/026 , G01N2333/52 , A61K2300/00
摘要： The present invention relates to zalpha11 Ligand polynucleotide and polypeptide molecules. The zalpha11 Ligand is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
摘要翻译：本发明涉及zalpha11配体多核苷酸和多肽分子。 zalpha11配体是一种新型细胞因子。多肽可用于在体外和体内刺激造血细胞的增殖和/或发育的方法中。本发明还包括生产蛋白质的方法，用途及其抗体。

8. 发明授权

US06565858B2 Human ADAMTS-1 protein and pharmaceutical composition 失效
标题翻译：人类ADAMTS-1蛋白和药物组成
公开(公告)号：US06565858B2
公开(公告)日：2003-05-20
申请号：US09445023
申请日：1999-12-03
申请人： Kunitaka Hirose , Eiji Inoguchi , Michinori Hakozaki , Keiko Ishioka , Yukako Ishida , Kouji Matsushima , Kouji Kuno
发明人： Kunitaka Hirose , Eiji Inoguchi , Michinori Hakozaki , Keiko Ishioka , Yukako Ishida , Kouji Matsushima , Kouji Kuno
IPC分类号： A61K4500
CPC分类号： G01N33/6872 , A23L33/17 , A61K38/00 , C07K14/47
摘要： A human ADAMTS-1 protein, a gene encoding the same, a pharmaceutical composition containing the protein as an active ingredient, and a method for immunologically analyzing the human ADAMTS-1 protein are disclosed. The protein can decrease the number of leukocytes and platelets, and at the same time, increase the number of erythrocytes.
摘要翻译：公开了人ADAMTS-1蛋白，编码该基因的基因，含有蛋白质作为活性成分的药物组合物和免疫分析人ADAMTS-1蛋白质的方法。蛋白质可以减少白细胞和血小板的数量，同时增加红细胞的数量。

9. 发明授权

US06528050B1 Growth factor homolog zvegf3 有权
标题翻译：生长因子同源物zvegf3
公开(公告)号：US06528050B1
公开(公告)日：2003-03-04
申请号：US09706968
申请日：2000-11-06
申请人： Zeren Gao , Charles E. Hart , Christopher S. Piddington , Paul O. Sheppard , Kimberly E. Shoemaker , Debra G. Gilbertson , James W. West
发明人： Zeren Gao , Charles E. Hart , Christopher S. Piddington , Paul O. Sheppard , Kimberly E. Shoemaker , Debra G. Gilbertson , James W. West
IPC分类号： A61K4500
CPC分类号： C07K14/52 , A01K2217/05 , A61K38/1858 , C07K14/475 , C12N2799/022
摘要： Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residues 235-345 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
摘要翻译：公开了多肽生长因子，其制备方法，编码它们的多核苷酸，针对它们的抗体以及使用它们的方法。多肽包含与SEQ ID NO：2的残基46-163或SEQ ID NO：2的残基235-345至少90％相同的氨基酸区段。还公开了多肽的多聚体。多肽，多聚体蛋白和多核苷酸可用于细胞和组织发育的研究和调节，作为细胞培养基的组分和诊断剂。

10. 发明授权

US06436388B2 Method of treating rhabdomyolysis by administering hepatocyte growth factor 有权
标题翻译：通过肝细胞生长因子治疗横纹肌溶解症的方法
公开(公告)号：US06436388B2
公开(公告)日：2002-08-20
申请号：US09381031
申请日：2000-02-24
申请人： Ikue Kudo , Tomokazu Nagano
发明人： Ikue Kudo , Tomokazu Nagano
IPC分类号： A61K4500
CPC分类号： A61K38/1833
摘要： The present invention is drawn to a method of treating acute renal failure caused by rhabdomyolysis by administering a therapeutically effective amount of hepatocyte growth factor (HGF). The present invention is further drawn to a method of treating rhabdomyolysis by administering a therapeutically effective amount of hepatocyte growth factor (HGF).
摘要翻译：本发明涉及通过施用治疗有效量的肝细胞生长因子（HGF）治疗由横纹肌溶解引起的急性肾功能衰竭的方法。本发明还涉及通过施用治疗有效量的肝细胞生长因子（HGF）来治疗横纹肌溶解症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式